Generic Medicine Info
May be taken with or without food.
Known hypersensitivity to telithromycin and other macrolides, history of hepatitis and/or jaundice associated w/ macrolide therapy, myasthenia gravis. Patient w/ congenital or known history of QT interval prolongation. Patient w/ renal or hepatic impairment receiving colchicine. Concomitant admin w/ drugs that prolong QT interval and are CYP3A4 substrates, HMG-CoA reductase inhibitors metabolised by CYP3A4 or ergot alkaloid derivatives.
Special Precautions
Patient w/ CHD, cardiac arrhythmias, hypokalaemia or hypomagnesaemia. Hepatic or renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause visual disturbances, confusion or hallucination, if affected, do not drive, operate heavy machinery or engage in other hazardous activities. Monitoring Parameters Perform LFTs. Closely monitor for signs and symptoms of liver failure (e.g. jaundice, fatigue, nausea, acholic stools) and visual acuity.
Adverse Reactions
Diarrhoea, nausea, vomiting, abdominal pain, flatulence, dizziness, headache, vertigo, insomnia, drowsiness, taste and smell disturbances, paraesthesia, eosinophilia, rash, arrhythmias, hypotension, bradycardia, visual disturbances, syncope, angioedema, anaphylaxis, erythema multiforme, muscle cramps.
Potentially Fatal: Hepatotoxicity including fulminant hepatitis, hepatic necrosis and hepatic failure, acute resp failure in patient w/ myasthenia gravis, Clostridium difficile-associated disease (CDAD).
Drug Interactions
Additive effect on QT interval prolongation w/ class 1A (e.g. quinidine, procainamide) or class III (e.g. dofetilide) antiarrhythmic agents. Decreased telithromycin concentrations and/or increased anticonvulsant concentrations w/ phenytoin, carbamazepine, phenobarbital. Increased peak plasma concentration and area under the concentration-time curve (AUC) w/ itraconazole and ketoconazole. Decreased peak plasma concentration and AUC w/ rifampicin. Increased AUC of midazolam or levonorgestrel. Increased plasma concentrations of colchicine, digoxin, repaglinide, ciclosporin, sirolimus or tacrolimus. May potentiate effects of oral anticoagulants (e.g. warfarin).
CIMS Class
ATC Classification
J01FA15 - telithromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on telithromycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in